JeanMarie Guenot, Ph.D., began her professional scientific career as chief scientist in clinical research and development for Hoffmann-La Roche. She harbored an intense ambition to discover perceptive cures for serious human ailments. Her earliest career pursuits involved the research of drugs for metabolism related ailments and autoimmune disorders. Guenot’s most recent focus has been in the field of Oncology on guenotllc.com. Today she is at the forefront of the medical fight against the ultimate human disease, cancer.
With over 20 years experience in pharmaceutical biotechnology, Jeanmarie Guenot has focused her immense knowledge towards tackling the problems with cancer attacking drugs. She has extensive experience in the way pharmaceutics relate to the medical profession. Dr. JeanMarie Guenot started completed her undergraduate studies, adding a Masters of Business Administration from the University of Pennsylvania. Her PhD gives Guenot the necessary insight to deal with the multifaceted medical and pharmaceutical industries. These skills on amphivena.com allow Guenot to be one of the most highly acclaimed experts in the field of ocular drug deliveries.
In April 2017, she was hailed for beginning a transformation of cancer drug philosophy. Even when current drugs reach the intended target and destroyed cancer cells; often the devastating side effects to adjoining tissue negates any gain for patients. Jeanmarie Guenot is guiding negotiations for a multi-million dollar equity transaction to expand the research of Biogen Idec-PDL 50:50 collaboration, which includes three various phases of cancer drug applications. This is maverick research toward closing the door on cancer in our future.
Jeanmarie Guenot’s record of achievements also includes the founding of SKS Ocular, a start-up pioneer in ophthalmic incubators. They specialized in ocular drug delivery and therapeutics for glaucoma patients. Guenot currently holds the highest management office at Amphivena Therapeutics, Inc. They are active in pharmaceutical developments exploring innovative treatments for hematologic malignancies and other types of antibody therapies.
Guenot’s project and management experience in the areas of oncology, cardiovascular disease, autoimmune disorders, neurology and ophthalmic illnesses, give her the insightful wisdom to guide cancer treatment forward. She continues to provide leadership and guidance at Amphivena Therapeutics, Inc., pursuing on her principal goal, which is to lead a new generation of cancer research. Dr. JeanMarie Guenot is truly a maverick in the fight against cancer.